Influence of Internal Structure and Composition of Liquid Crystalline Phases on Topical Delivery of Paclitaxel

被引:47
作者
Hosmer, Jaclyn M. [1 ]
Shin, Soo H. [1 ]
Nornoo, Adwoa [2 ]
Zheng, Haian [1 ]
Lopes, Luciana B. [1 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Albany, NY 12208 USA
[2] Palm Beach Atlantic Univ, Gregory Sch Pharm, W Palm Beach, FL USA
关键词
paclitaxel; skin; lamellar phase; hexagonal phase; transdermal; permeation enhancers; formulation; lipids; DRUG-DELIVERY; TRANSDERMAL DELIVERY; IN-VITRO; PERCUTANEOUS-ABSORPTION; DERMAL DELIVERY; MICROEMULSIONS; ENHANCEMENT; NANOPARTICLES; CYTOTOXICITY; FORMULATIONS;
D O I
10.1002/jps.22370
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study aimed to evaluate whether and how the internal structure and composition of liquid crystalline systems can be tailored to maximize paclitaxel cutaneous delivery. Liquid crystalline phases of water, Brij-97, and medium-chain mono/diglycerides (MCG) were characterized by polarized light microscopy. Lamellar phases containing 20% (w/w) water and MCG at 10% (LP-10) or 20% (LP-20), and a hexagonal phase (HP) with 45% water and 10% MCG were selected; paclitaxel was incorporated at 0.5% (w/w). Compared with drug solution in myvacet oil, LP-20 provided the highest paclitaxel cutaneous delivery (threefold), and LP-10 the highest transdermal delivery (fourfold). Using a fluorescent drug derivative [at 0.5%, (w/w)], we observed that penetration occurred through intact stratum corneum. To evaluate whether penetration results relate to drug release differences, paclitaxel self-diffusion coefficient (D) and in vitro release were studied. D was the highest in LP-20, but release from LP-20 and LP-10 was similar. The low D in HP was associated with the lowest drug release. As an index of efficacy, we assessed the cytotoxicity of paclitaxel-loaded LP-20 against fibroblasts. Cell viability was 1.3-2 times smaller with LP-20 than with drug solution. Our results demonstrate that LP-20 provides optimization of paclitaxel cutaneous delivery and efficient cytotoxicity. (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:1444-1455, 2011
引用
收藏
页码:1444 / 1455
页数:12
相关论文
共 45 条
[1]   Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines [J].
Akhlaghi, Seyedeh Parinaz ;
Saremi, Shahrooz ;
Ostad, Seyed Nasser ;
Dinarvand, Rassoul ;
Atyabi, Fatemeh .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2010, 6 (05) :689-697
[2]   Enhancement of topical delivery from biodegradable nanoparticles [J].
Alvarez-Román, R ;
Naik, A ;
Kalia, YN ;
Guy, RH ;
Fessi, H .
PHARMACEUTICAL RESEARCH, 2004, 21 (10) :1818-1825
[3]   Kaposi's sarcoma [J].
Antman, K ;
Chang, Y .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) :1027-1038
[4]   Paclitaxel for progressive basal cell carcinoma [J].
Barceló, R ;
Viteri, A ;
Muñoz, A ;
Gil-Negrete, A ;
Rubio, I ;
López-Vivanco, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (02) :S50-S52
[5]   Novel mechanisms and devices to enable successful transdermal drug delivery [J].
Barry, BW .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (02) :101-114
[6]   Lipid cubic phases for improved topical drug delivery in photodynamic therapy [J].
Bender, J ;
Ericson, MB ;
Merclin, N ;
Iani, V ;
Rosén, A ;
Engström, S ;
Moan, J .
JOURNAL OF CONTROLLED RELEASE, 2005, 106 (03) :350-360
[7]   Percutaneous absorption of sunscreens from liquid crystalline phases [J].
Brinon, L ;
Geiger, S ;
Alard, V ;
Doucet, J ;
Tranchant, JF ;
Couarraze, G .
JOURNAL OF CONTROLLED RELEASE, 1999, 60 (01) :67-76
[8]   Drug delivery from a liquid crystalline base across Visking and human stratum corneum [J].
Carr, MG ;
Corish, J ;
Corrigan, OI .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 157 (01) :35-42
[9]   AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy [J].
Cheung, MC ;
Pantanowitz, L ;
Dezube, BJ .
ONCOLOGIST, 2005, 10 (06) :412-426
[10]   PERCUTANEOUS-ABSORPTION AND DERMAL DELIVERY OF CYCLOSPORINE-A [J].
CHOI, HK ;
FLYNN, GL ;
AMIDON, GL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (05) :581-583